Nabumetone Accord-Uk (Nabumetone)

Nabumetone is a pro‑drug that is converted in the body to an active metabolite which reversibly blocks cyclooxygenase‑1 and cyclooxygenase‑2 enzymes. This blockade reduces prostaglandin production, thereby diminishing inflammation, pain, and fever.

The specific dose of nabumetone is determined by the prescribing clinician based on the patient’s condition, severity, age, and renal or hepatic function. Typical adult dosing ranges are established in clinical guidelines, but the exact regimen should be individualized by a healthcare professional.

Safety data for nabumetone during pregnancy and lactation are limited, and the drug is generally classified as contraindicated or to be used only if the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nabumetone shares the core anti‑inflammatory and analgesic actions of other NSAIDs but is a pro‑drug, which may result in a slightly different gastrointestinal tolerability profile. Compared with ibuprofen or diclofenac, it may have a longer half‑life, allowing once‑daily dosing in many cases, though individual response varies.

Store Nabumetone Accord-Uk at ambient temperature, below 25 °C, in the original packaging. Protect the tablets from moisture, direct sunlight, and excessive heat to maintain product stability throughout its shelf life.

Nabumetone Accord-Uk is taken orally, usually with a full glass of water. It may be taken with or without food, but patients who experience stomach upset are advised to ingest it with meals to lessen gastrointestinal irritation.

Serious risks include gastrointestinal bleeding or ulceration, severe liver injury, acute kidney damage, cardiovascular events such as heart attack or stroke, and rare but life‑threatening skin reactions. Patients should seek immediate medical attention if they notice signs like black stools, jaundice, sudden swelling, or rash.

Nabumetone is contraindicated in individuals with known hypersensitivity to nabumetone or other NSAIDs, active peptic ulcer disease, severe heart failure, significant renal or hepatic impairment, and in patients who have had recent coronary artery bypass surgery. It should also be avoided in the third trimester of pregnancy.